Search clinical trials for: Treprostinil Palmitil Inhalation Powder

Total 183 results

Insmed Incorporated

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Healthy Volunteers

United States
Insmed Incorporated

Recruiting

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Pulmonary Hypertension | Interstitial Lung Disease

Belgium, Germany, Spain, Italy, Argentina, Australia, United Kingdom
Mannkind Corporation

Completed

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

Pulmonary Arterial Hypertension

United States
Insmed Incorporated

Completed

A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Pulmonary Hypertension

Belgium, Germany, Spain, Argentina, Australia, Italy, United Kingdom
Insmed Incorporated

Terminated

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States
Insmed Incorporated

Recruiting

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Argentina, Austria, Brazil, Germany, Italy, Malaysia, Philippines, Spain, United Kingdom, Serbia, Japan, United States, Mexico, Denmark
Insmed Incorporated

Recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, Argentina, Australia, Belgium, Brazil, Germany, Italy, Japan, Malaysia, Mexico, Philippines, Switzerland, United Kingdom, Serbia, Austria, Denmark
United Therapeutics

Completed

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso (BREEZE)

Pulmonary Arterial Hypertension

United States
Pharmosa Biopharm Inc.
PPD

Completed

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

Pulmonary Arterial Hypertension

United States
Lung Biotechnology PBC

Terminated

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis | Pulmonary Hypertension

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects

Chronic Obstructive Pulmonary Disease

China
AlgiPharma AS
Imperial College London; Cystic Fibrosis Foundation; University Hospital of Cologne and other collaborators

Withdrawn

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis (SMR3372)

Cystic Fibrosis

Germany
Liquidia Technologies, Inc.
FGK Clinical Research GmbH

Terminated

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Pulmonary Arterial Hypertension

France, Germany
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
Mannkind Corporation

Completed

A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males

Diabetes Mellitus, Type 2 | Healthy Males

Netherlands
Mannkind Corporation

Completed

Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719/GW642444 in Japanese (DB2115362)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
GlaxoSmithKline

Completed

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
United Therapeutics

Completed

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

Pulmonary Arterial Hypertension

United States
University of North Carolina, Chapel Hill
United Therapeutics

Terminated

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

Respiratory Distress Syndrome, Adult

United States
Mannkind Corporation

Completed

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Netherlands
GlaxoSmithKline

Completed

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Russian Federation, Poland
United Therapeutics

Completed

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) (TRIUMPH)

Pulmonary Hypertension

United States, Israel, Austria, United Kingdom, Belgium, France, Germany, Ireland, Italy, Spain
Savara Inc.

Completed

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

Cystic Fibrosis | MRSA

United States, Canada
Mannkind Corporation

No longer available

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Type 1 Diabetes | Type 2 Diabetes

United States
GlaxoSmithKline

Completed

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Ukraine, Poland
Savara Inc.
Cystic Fibrosis Foundation; Synteract, Inc.

Completed

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

Cystic Fibrosis

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Germany, Estonia, Chile, Netherlands, Peru, South Africa, Sweden, Mexico, United Kingdom, Italy, Philippines, Canada
GlaxoSmithKline

Completed

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, Argentina, Germany, Spain, South Africa, Mexico, Peru, Netherlands, Canada, United Kingdom, Denmark, Chile, Italy, Sweden
Mannkind Corporation

Terminated

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Mannkind Corporation

Completed

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

Diabetes Mellitus | Mild Nephropathy | Moderate Nephropathy

United States
Chiesi Farmaceutici S.p.A.

Completed

Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device

COPD

Belgium
Mannkind Corporation

Completed

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Diabetes Mellitus: Type 1

United States
GlaxoSmithKline

Completed

GSK573719 IV Enabling Study

Pulmonary Disease, Chronic Obstructive

United Kingdom
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment

COPD

Turkey
Stanford University
Northwestern University

Completed

A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

Hypertension, Pulmonary

United States
Respira Therapeutics, Inc.

Completed

A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Australia
Mannkind Corporation

Completed

A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)

Healthy Subjects

United States
Respira Therapeutics, Inc.

Completed

A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234

Healthy Volunteer

Australia
Novartis Pharmaceuticals

Completed

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis (EAGER)

Cystic Fibrosis

United States, Germany, United Kingdom, Colombia, Spain, France, Netherlands, Israel, Canada, Italy, Chile, Australia, Hungary, Mexico
Universidade do Porto

Completed

Motivational Interviewing in Physiotherapy for Patients With Low Back Pain (HELENA)

Motivational Interviewing
GlaxoSmithKline

Completed

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

Asthma

Germany, Ukraine, United States, Peru, Poland
Amorphical Ltd.

Completed

Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.

Covid19

Israel
Novartis Pharmaceuticals

Completed

Open Label Extension to Bridging Study CTBM100C2303

Cystic Fibrosis | Pseudomonas Aeruginosa

Russian Federation, Estonia
Boston Children's Hospital

Terminated

Asthma (and Dietary) Inflammation Reduction (AIR)

Asthma

United States
Novartis

Terminated

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects (EVOLVE)

Cystic Fibrosis

United States, Argentina, Brazil, Bulgaria, Canada, Chile, Lithuania, Mexico
Novartis Pharmaceuticals

Completed

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)

Cystic Fibrosis

Spain, Germany, Switzerland, United Kingdom, Ireland
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Mexico, Norway
Mannkind Corporation

Completed

Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes

Diabetes Type 2

United States

3

Subscribe